Lifesci Capital Brokers Lower Earnings Estimates for AQST

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Equities research analysts at Lifesci Capital decreased their Q2 2026 EPS estimates for Aquestive Therapeutics in a research note issued on Friday, May 15th. Lifesci Capital analyst F. Brisebois now anticipates that the company will earn ($0.12) per share for the quarter, down from their prior forecast of ($0.11). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. Lifesci Capital also issued estimates for Aquestive Therapeutics’ Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.48) EPS.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Wednesday, May 13th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. The company had revenue of $14.45 million during the quarter, compared to analyst estimates of $10.90 million.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Monday, April 20th. Lake Street Capital set a $6.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, February 3rd. Oppenheimer assumed coverage on shares of Aquestive Therapeutics in a research report on Friday, April 24th. They issued an “outperform” rating and a $8.00 target price on the stock. Finally, Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $8.80.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $4.14 on Tuesday. The firm’s 50-day moving average is $4.16 and its two-hundred day moving average is $4.74. Aquestive Therapeutics has a 12 month low of $2.22 and a 12 month high of $7.55. The stock has a market capitalization of $519.36 million, a P/E ratio of -6.79 and a beta of 1.50.

Insider Buying and Selling at Aquestive Therapeutics

In other news, CFO A Ernest Toth, Jr. sold 58,254 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total transaction of $242,919.18. Following the sale, the chief financial officer owned 376,112 shares of the company’s stock, valued at approximately $1,568,387.04. This represents a 13.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Barber sold 8,257 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $4.29, for a total transaction of $35,422.53. Following the sale, the chief executive officer directly owned 660,574 shares in the company, valued at $2,833,862.46. This represents a 1.23% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 403,947 shares of company stock valued at $1,685,450. Corporate insiders own 6.81% of the company’s stock.

Institutional Trading of Aquestive Therapeutics

Hedge funds have recently made changes to their positions in the business. Aberdeen Group plc acquired a new stake in shares of Aquestive Therapeutics during the third quarter worth about $3,494,000. Blue Owl Capital Holdings LP increased its stake in shares of Aquestive Therapeutics by 35.9% during the third quarter. Blue Owl Capital Holdings LP now owns 1,250,000 shares of the company’s stock worth $6,988,000 after buying an additional 330,000 shares during the period. Federated Hermes Inc. purchased a new stake in shares of Aquestive Therapeutics during the third quarter worth approximately $4,381,000. Sugar Maple Asset Management LLC increased its stake in shares of Aquestive Therapeutics by 357.1% during the fourth quarter. Sugar Maple Asset Management LLC now owns 54,850 shares of the company’s stock worth $354,000 after buying an additional 42,850 shares during the period. Finally, Lineweaver Wealth Advisors LLC purchased a new stake in shares of Aquestive Therapeutics during the fourth quarter worth approximately $65,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.